688 related articles for article (PubMed ID: 17241127)
21. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
[TBL] [Abstract][Full Text] [Related]
22. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
Coune PG; Bensadoun JC; Aebischer P; Schneider BL
J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
[TBL] [Abstract][Full Text] [Related]
23. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
24. Melatonin prevents dopaminergic cell loss induced by lentiviral vectors expressing A30P mutant alpha-synuclein.
Brito-Armas JM; Baekelandt V; Castro-Hernández JR; González-Hernández T; Rodríguez M; Castro R
Histol Histopathol; 2013 Aug; 28(8):999-1006. PubMed ID: 23444197
[TBL] [Abstract][Full Text] [Related]
25. Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra.
Garcia-Reitboeck P; Anichtchik O; Dalley JW; Ninkina N; Tofaris GK; Buchman VL; Spillantini MG
Exp Neurol; 2013 Oct; 248():541-5. PubMed ID: 23933574
[TBL] [Abstract][Full Text] [Related]
26. Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration.
Van Rompuy AS; Oliveras-Salvá M; Van der Perren A; Corti O; Van den Haute C; Baekelandt V
Mol Neurodegener; 2015 Jun; 10():23. PubMed ID: 26099628
[TBL] [Abstract][Full Text] [Related]
27. Could a loss of alpha-synuclein function put dopaminergic neurons at risk?
Perez RG; Hastings TG
J Neurochem; 2004 Jun; 89(6):1318-24. PubMed ID: 15189334
[TBL] [Abstract][Full Text] [Related]
28. Cre-dependent AAV vectors for highly targeted expression of disease-related proteins and neurodegeneration in the substantia nigra.
Grames MS; Dayton RD; Jackson KL; Richard AD; Lu X; Klein RL
FASEB J; 2018 Aug; 32(8):4420-4427. PubMed ID: 29513569
[TBL] [Abstract][Full Text] [Related]
29. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.
Fornai F; Lenzi P; Ferrucci M; Lazzeri G; di Poggio AB; Natale G; Busceti CL; Biagioni F; Giusiani M; Ruggieri S; Paparelli A
Brain Res Bull; 2005 May; 65(5):405-13. PubMed ID: 15833595
[TBL] [Abstract][Full Text] [Related]
30. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
[TBL] [Abstract][Full Text] [Related]
31. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice.
Wakamatsu M; Ishii A; Iwata S; Sakagami J; Ukai Y; Ono M; Kanbe D; Muramatsu S; Kobayashi K; Iwatsubo T; Yoshimoto M
Neurobiol Aging; 2008 Apr; 29(4):574-85. PubMed ID: 17174013
[TBL] [Abstract][Full Text] [Related]
32. Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra.
von Bohlen und Halbach O; Minichiello L; Unsicker K
FASEB J; 2005 Oct; 19(12):1740-2. PubMed ID: 16037097
[TBL] [Abstract][Full Text] [Related]
33. Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.
Khodr CE; Becerra A; Han Y; Bohn MC
Brain Res; 2014 Mar; 1550():47-60. PubMed ID: 24463035
[TBL] [Abstract][Full Text] [Related]
34. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
35. Identification and kainic acid-induced up-regulation of low-affinity p75 neurotrophin receptor (p75NTR) in the nigral dopamine neurons of adult rats.
Wang YQ; Bian GL; Bai Y; Cao R; Chen LW
Neurochem Int; 2008 Sep; 53(3-4):56-62. PubMed ID: 18639597
[TBL] [Abstract][Full Text] [Related]
36. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons.
Mosharov EV; Larsen KE; Kanter E; Phillips KA; Wilson K; Schmitz Y; Krantz DE; Kobayashi K; Edwards RH; Sulzer D
Neuron; 2009 Apr; 62(2):218-29. PubMed ID: 19409267
[TBL] [Abstract][Full Text] [Related]
37. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
[TBL] [Abstract][Full Text] [Related]
38. FOXO3 determines the accumulation of α-synuclein and controls the fate of dopaminergic neurons in the substantia nigra.
Pino E; Amamoto R; Zheng L; Cacquevel M; Sarria JC; Knott GW; Schneider BL
Hum Mol Genet; 2014 Mar; 23(6):1435-52. PubMed ID: 24158851
[TBL] [Abstract][Full Text] [Related]
39. Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease.
Yasuda T; Nihira T; Ren YR; Cao XQ; Wada K; Setsuie R; Kabuta T; Wada K; Hattori N; Mizuno Y; Mochizuki H
J Neurochem; 2009 Feb; 108(4):932-44. PubMed ID: 19141079
[TBL] [Abstract][Full Text] [Related]
40. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]